pyrazolanthrone has been researched along with Cardiomyopathy, Dilated in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonne, G; Muchir, A; Shan, J; Worman, HJ; Wu, W | 1 |
| Akita, Y; Enoki, C; Fujiwara, H; Imamura, H; Iwasaka, T; Kamihata, H; Kyoi, S; Matsuhisa, S; Otani, H; Tatsumi, K | 1 |
2 other study(ies) available for pyrazolanthrone and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene.
Topics: Animals; Anthracenes; Cardiomyopathy, Dilated; Fibrosis; Flavonoids; Heart Function Tests; Lamin Type A; Male; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinases; Mutation; Myocardium; Pilot Projects; Protein Kinase Inhibitors | 2011 |
Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster.
Topics: Animals; Anthracenes; Apoptosis; Cardiomyopathy, Dilated; Cricetinae; Fibrosis; Imidazoles; Immunoblotting; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Male; Microscopy, Fluorescence; Myocardium; p38 Mitogen-Activated Protein Kinases; Pyrazoles; Pyridines; Ventricular Dysfunction, Left | 2006 |